If you would like to give to a specific research program or support the work of a particular researcher, contact our fundraising team today.
Project name | Therapeutic areas | Stage | Mode of action |
---|---|---|---|
Safer CAR-T cells | Cancer | Hit Discovery | Cell therapy |
High affinity dual-specificity biologics | Cancer | Hit Discovery | Cell therapy |
Next generation DC therapy | Cancer | Hit Discovery | Cell therapy |
pDC therapy for lupus | Immunology and inflammation | Hit Discovery | Inhibitor |
Epigenetic inhibitor | Immunology and inflammation | Hit Discovery | Inhibitor |
Mucolytics | Immunology and inflammation | Target Validation | Biologic |
VirPRO – targeting MPro | Global health and infection | Hit-to-Lead | Inhibitor |
VirPRO – targeting PLPro | Global health and infection | Hit-to-Lead | Inhibitor |
c-FIND – rapid points of care diagnostic | Global health and infection | Hit Discovery | Diagnostic |
Toxoplasma Vaccine | Global health and infection | Hit Discovery | Vaccine |
Antihelminth therapy | Global health and infection | Hit Discovery | Inhibitor |
Precision epigenetics | Neurological disorders | Hit-to-Lead | Inhibitor |
Preventing cell loss in retinal disease | Neurological disorders | Hit Discovery | Inhibitor |
Rare genetic disorders diagnostics | Neurological disorders | Target Validation | Diagnostic |
IL-11 signaling | Platform technologies | Hit Discovery | Biologic |
E3 ligase warheads | Platform technologies | Hit Discovery | Protein degrader |
Genomic orchestration engine | Digital health | Successful pilots | Software |